Many laboratories are developing testing of cell free DNA (cfDNA) to detect the presence of pathogenic gene variants in plasma samples. As the clinical utility of this testing is recognised, the requirement for the number of targets tested is increasing. In order to help laboratories develop and deliver high quality testing, IQN Path plans to deliver an external quality assessment (EQA) for testing plasma samples for the detection of multiple targets.

To provide an EQA which is useful to laboratories we would like to collect information from potential participants to determine the targets currently tested, research and development underway and plans for future implementation of multiple targets, therefore we invite you to complete this survey.

Question Title

* 1. Please provide your details.

Question Title

* 2. Are you a member of a laboratory providing molecular pathology testing?

0 of 32 answered